Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12483
Title: Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease.
Authors: Watt, Andrew D;Perez, Keyla A;Ang, Ching-Seng;O'Donnell, Paul;Rembach, Alan;Pertile, Kelly K;Rumble, Rebecca L;Trounson, Brett O;Fowler, Christopher J;Faux, Noel G;Masters, Colin L;Villemagne, Victor L;Barnham, Kevin J
Affiliation: The Florey Institute of Neuroscience and Mental Health, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia The Neuroproteomics Platform, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
The Florey Institute of Neuroscience and Mental Health, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
The Florey Institute of Neuroscience and Mental Health, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.
The Florey Institute of Neuroscience and Mental Health, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia Department of Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia The Neuroproteomics Platform, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
Issue Date: 2015
Citation: Journal of Alzheimer's Disease : Jad; 44(4): 1131-43
Abstract: Biomarkers enabling the preclinical identification of Alzheimer's disease (AD) remain one of the major unmet challenges in the field. The blood cellular fractions offer a viable alternative to current cerebrospinal fluid and neuroimaging modalities. The current study aimed to replicate our earlier reports of altered binding within the AD-affected blood cellular fraction to copper-loaded immobilized metal affinity capture (IMAC) arrays. IMAC and anti-amyloid-β (Aβ) antibody arrays coupled with mass spectrometry were used to analyze blood samples collected from 218 participants from within the AIBL Study of Aging. Peripheral Aβ was fragile and prone to degradation in the AIBL samples, even when stored at -80°C. IMAC analysis of the AIBL samples lead to the isolation and identification of alpha-defensins 1 and 2 at elevated levels in the AD periphery, validating earlier findings. Alpha-defensins 1 and 2 were elevated in AD patients indicating that an inflammatory phenotype is present in the AD periphery; however, peripheral Aβ levels are required to supplement their prognostic power.
Internal ID Number: 25408207
URI: http://ahro.austin.org.au/austinjspui/handle/1/12483
DOI: 10.3233/JAD-142286
URL: http://www.ncbi.nlm.nih.gov/pubmed/25408207
Type: Journal Article
Subjects: Alzheimer's disease
amyloid-β
biomarkers
blood
inflammation
mass spectrometry
α-defensins
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.